Avanir Pharmaceuticals

Concert Pharmaceuticals has achieved a $2 million (£1.3m) milestone under its development and license agreement with Avanir Pharmaceuticals for the phase three initiation of AVP-786 for agitation in patients with Alzheimer’s Read more


The milestone is a result of Avanir initiating dosing in a Phase II clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. Read more